NTRA logo

NTRA Natera Inc

$410.35
$1.88
(0.46%)
Today
Closed $410.35
$0.89
(0.22%)
After Hours
46

Neutral Sentiment

How do you feel about NTRA?

Loading...
$1000 Invested In Natera 5 Years Ago Would Be Worth This Much Today
Natera (NASDAQ:NTRA) has outperformed the market over the past 5 years by 17.64% on an annualized basis producing an average annual return of 29.65%. Currently, Natera has a market capitalization of $59.35 billion.read more...
Benzinga
Natera, UnitedHealth Group And A Tech Stock On CNBC's 'Final Trades'
CNBC's Final Trades: Rob Sechan picks Hewlett Packard, Kevin Simpson favors Natera, and Stephen Weiss recommends UnitedHealth.read more...
Benzinga
Natera's Signatera Wins Japan PMDA Approval as Bladder Cancer CDx
NTRA wins Japan PMDA approval for Signatera in muscle-invasive bladder cancer, supporting treatment decisions and a planned 2027 commercial launch.
Zacks
NTRA Stock Hits All-Time High, OMER Stock Scales 5-Year Peak – What’s Driving Investors’ Enthusiasm Today?
Natera’s Signatera test secured a key regulatory approval, while Cantor raised its sales expectations for Omeros’ lead drug, Yartemlea.
Stocktwits
Natera Announces Japan's PMDA Authorization For Signatera In Muscle-Invasive Bladder Cancer
(RTTNews) - Natera, Inc. (NTRA) announced that its Signatera test has received regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency as a companion diagnostic in muscle-invasive bladder cancer. The approval supports the use of the Signatera test to guide ad...
Nasdaq News: Markets
Uber, Micron, Datadog And A Health Care Stock: CNBC's 'Final Trades'
CNBC's Final Trades featured Uber, Micron, Natera and Datadog, with analysts citing bullish views and all four stocks posting gains.read more...
Benzinga
Signatera Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its Signatera test has received regulatory approval from Japans Pharmaceuticals and Medical Devices Agency (PMDA) as a companion diagnostic (CDx) in muscle-invasive bladder cancer (MIBC). This...
Business Wire
Natera CEO Steven Chapman Sells 1,698 Shares for $545,000
Key PointsThe disposal represented 2% of the total equity stake held by the executive prior to the transaction...
Nasdaq News: Markets
Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data that was recently presented at the IASLC 2026 World Conference on Lung Cancer (WCLC) in Seoul, South Korea. Natera and its collaborators presented four abstracts, including two oral...
Business Wire